Goal of the analysis:
Determine the feasibility, strategic fit, and regulatory pathway for developing a diagnostic test in parallel with a therapeutic product. Identify how the diagnostic will guide therapy decisions, evaluate market potential, and ensure alignment with both device and pharmaceutical regulatory requirements.
Data required:
- Information on the therapeutic product’s mechanism of action, target patient population, and clinical trial designs
- Biomarkers or relevant biological targets that correlate with therapeutic response
- Preliminary or existing clinical data supporting the use of the diagnostic for patient stratification or therapy monitoring
- Regulatory guidelines for companion diagnostics (for example, FDA, EMA, PMDA)
- Market research on the prevalence of targeted conditions, competitive landscape, and reimbursement perspectives for diagnostic tests
- Intellectual property (IP) status of biomarkers or diagnostic technologies
Detailed step-by-step instruction on how to conduct the analysis:
- Define the therapeutic and diagnostic link. Clearly articulate how the diagnostic test identifies the patient subset most likely to benefit from the therapy or monitors therapy response.
- Assess technical feasibility and validation pathways. Evaluate the biomarker’s clinical relevance, required diagnostic performance metrics (sensitivity, specificity), and any analytical validation needs.
- Review regulatory considerations. Determine whether a coordinated submission or parallel review process is applicable. Identify the lead agency groups (for example, FDA’s CDRH and CDER for the US).
- Analyze clinical trial integration. Examine how the diagnostic will be incorporated into therapeutic clinical studies (for example, patient inclusion/exclusion, endpoint definitions, sample collection protocols).
- Estimate development timelines and costs. Account for additional testing, regulatory fees, trial enrollment challenges, and manufacturing scale-up for the diagnostic component.
- Evaluate market access and reimbursement factors. Consider whether payers will view the companion diagnostic as a clinically necessary tool, thus supporting coverage and coding pathways.
- Identify potential strategic partners. Determine if the company should develop the diagnostic internally or collaborate with a diagnostic specialist, factoring in IP, technical expertise, and resource availability.
- Develop a co-development roadmap. Outline major milestones, including assay design and validation, clinical trial integration, regulatory submissions, and commercial launch.
Format of the output of analysis:
- A co-development strategy document summarizing the rationale for linking the diagnostic and therapeutic
- A timeline or Gantt chart mapping parallel development activities for both the drug and the diagnostic
- A market analysis and financial model estimating potential revenue, costs, and return on investment
- An executive summary highlighting the clinical rationale, expected regulatory pathway, and recommended next steps
How to interpret results:
- A clear, evidence-based link between the diagnostic test and therapeutic efficacy indicates a strong case for a companion diagnostic approach, potentially improving market adoption and reimbursement.
- Regulatory complexity or significant data gaps can delay co-development, requiring additional validation or the involvement of specialized partners.
- The economic viability of a companion diagnostic often hinges on demonstrating improved patient outcomes, which justifies reimbursement for the test.
Steps a company can take to improve on this measure:
- Engage early with regulatory authorities (for example, through pre-submission meetings) to clarify co-development requirements and coordinate review pathways.
- Collaborate with academic or biotech partners who have expertise in biomarker discovery and assay development.
- Secure robust clinical evidence by designing trials that clearly demonstrate how the diagnostic improves treatment selection or outcomes.
- Develop a comprehensive reimbursement strategy, detailing the clinical and economic value of the companion diagnostic to payers and providers.
- Continuously update the co-development plan as clinical, regulatory, or market dynamics evolve to maintain alignment and mitigate risks.
